Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Selective side-chain modification of cysteine and arginine residues blocks pathogenic activity of HIV-1-Tat functional peptides.

Devadas K, Boykins RA, Hardegen NJ, Philp D, Kleinman HK, Osa EO, Wang J, Clouse KA, Wahl LM, Hewlett IK, Rappaport J, Yamada KM, Dhawan S.

Peptides. 2006 Apr;27(4):611-21. Epub 2005 Oct 26.

PMID:
16256245
2.

Mechanisms for macrophage-mediated HIV-1 induction.

Devadas K, Hardegen NJ, Wahl LM, Hewlett IK, Clouse KA, Yamada KM, Dhawan S.

J Immunol. 2004 Dec 1;173(11):6735-44.

3.

Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection.

Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, Hardegen N, Wild CT, Wahl SM.

J Exp Med. 2004 Nov 15;200(10):1337-46.

4.

Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM.

J Exp Med. 2003 Dec 15;198(12):1875-86.

5.
6.

HIV-1 infects and alters immune function of a monocyte subset expressing low CD14 surface phenotype.

Hardegen NJ, Toro LA, Muller J, Wahl LM, Hewlett IK, Dhawan S.

Viral Immunol. 2000;13(1):19-26.

PMID:
10733165
8.

Lipopolysaccharide heterogeneity in Escherichia coli J5 variants: analysis by flow cytometry.

Evans ME, Pollack M, Koles NL, Hardegen NJ, Panopoulos D.

J Infect Dis. 1992 Oct;166(4):803-11.

PMID:
1527415
9.

Fluorescence-activated cell sorter analysis of binding by lipopolysaccharide-specific monoclonal antibodies to gram-negative bacteria.

Evans ME, Pollack M, Hardegen NJ, Koles NL, Guelde G, Chia JK.

J Infect Dis. 1990 Jul;162(1):148-55.

PMID:
2355191

Supplemental Content

Loading ...
Support Center